BioAtla, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a nine-month net loss of $13.789 million and total assets of $1.109 million as of that date.

Key Highlights

  • Nine-month net loss: The company reported a consolidated net loss of $13.789 million for the nine months ended September 30, 2026, compared to $49.823 million for the same period in 2025.
  • Cash position: Cash and cash equivalents stood at $576 thousand as of September 30, 2026, down from $7.118 million at December 31, 2025.
  • Total assets: Total assets were $1.109 million at September 30, 2026, compared to $13.828 million at December 31, 2025.
  • Stockholders' deficit: Total stockholders' deficit was $(43.596) million at September 30, 2026, versus $(36.189) million at December 31, 2025.
  • Collaboration revenue: The company recorded $6.750 million in collaboration and other revenue for the nine months ended September 30, 2026, compared to $0 for the same period in 2025.
  • Shares outstanding: As of November 11, 2026, the company reported 1,666,100 shares of common stock outstanding and 0 shares of Class B common stock outstanding.
  • Lease impairment: The filing reported an impairment of operating lease right-of-use asset of $4.858 million in the three months ended September 30, 2026.

BioAtla's Financial Position and Operations Through September 30, 2026

According to the filing, BioAtla, Inc. (OTC QB Venture Market:BCAB) reported a consolidated net loss of $7.897 million for the three months ended September 30, 2026, compared to a net loss of $15.778 million for the same quarter in 2025. For the nine-month period, the net loss was $13.789 million versus $49.823 million in the prior-year period. The company disclosed $250 thousand in collaboration and other revenue for the third quarter of 2026, with no corresponding revenue reported in the third quarter of 2025.

The filing disclosed that total operating expenses for the nine months ended September 30, 2026 were $24.186 million, down from $50.050 million in the nine months ended September 30, 2025. Research and development expense for the nine-month period was $9.335 million, compared to $35.578 million in the prior-year period. General and administrative expense was $9.993 million for the nine months ended September 30, 2026, versus $14.472 million in the same period of 2025. Additionally, the company recorded a $4.858 million impairment of operating lease right-of-use asset in the three months ended September 30, 2026, with no comparable charge in 2025.

The balance sheet as of September 30, 2026 showed total liabilities of $44.705 million, including accounts payable and accrued expenses of $18.857 million and a liability to licensor of $19.806 million. The accumulated deficit reached $559.435 million at September 30, 2026. During the nine months ended September 30, 2026, the company issued 334,144 shares of common stock under Pre-Purchase Agreements (PPAs), generating $3.869 million in additional paid-in capital, and issued 48,092 shares under a Standby Equity Purchase Agreement (SEPA), generating $413 thousand. The warrant liability decreased from $3.516 million at December 31, 2025 to $168 thousand at September 30, 2026, with the filing reporting a gain on warrant liability of $3.348 million for the nine-month period.

What Was Disclosed

BioAtla filed a Form 10-Q for the quarterly period ended September 30, 2026, reporting a nine-month net loss of $13.789 million, cash of $576 thousand, total assets of $1.109 million, and a total stockholders' deficit of $43.596 million, alongside $6.750 million in collaboration revenue year-to-date.